Published in Endocr Relat Cancer on August 23, 2013
Current approaches and recent developments in the management of head and neck paragangliomas. Endocr Rev (2014) 1.07
Krebs cycle metabolite profiling for identification and stratification of pheochromocytomas/paragangliomas due to succinate dehydrogenase deficiency. J Clin Endocrinol Metab (2014) 0.97
Peptide receptor radionuclide therapy with (90)Y/ (177)Lu-labelled peptides for inoperable head and neck paragangliomas (glomus tumours). Eur J Nucl Med Mol Imaging (2015) 0.78
Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: Paragangliomas. Head Neck Pathol (2017) 0.75
Evaluation of Head and Neck Paragangliomas by Computed Tomography in Patients with Pheochromocytoma-Paraganglioma Syndromes. Pol J Radiol (2016) 0.75
Cushing's syndrome. Lancet (2006) 5.19
Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab (2008) 4.68
The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab (2002) 3.43
Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005. Nat Clin Pract Endocrinol Metab (2007) 3.25
AIP mutation in pituitary adenomas in the 18th century and today. N Engl J Med (2011) 3.14
The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev (2004) 2.88
The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term follow-up. J Clin Endocrinol Metab (2005) 2.80
Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf) (2009) 2.62
The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocr Relat Cancer (2007) 2.10
Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver. Hepatology (2008) 2.07
Ghrelin--a hormone with multiple functions. Front Neuroendocrinol (2004) 1.88
Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase. J Biol Chem (2005) 1.83
Clinical review: Diagnosis and management of pituitary carcinomas. J Clin Endocrinol Metab (2005) 1.79
123I-metaiodobenzylguanidine (MIBG) scintigraphy for the detection of adrenal and extra-adrenal phaeochromocytomas: CT and MRI correlation. Clin Endocrinol (Oxf) (2008) 1.78
Etomidate in the management of hypercortisolaemia in Cushing's syndrome: a review. Eur J Endocrinol (2012) 1.73
The value of the low-dose dexamethasone suppression test in the differential diagnosis of hyperandrogenism in women. J Clin Endocrinol Metab (2003) 1.61
Discriminatory value of the low-dose dexamethasone suppression test in establishing the diagnosis and differential diagnosis of Cushing's syndrome. J Clin Endocrinol Metab (2003) 1.60
Unmasking of central hypothyroidism following growth hormone replacement in adult hypopituitary patients. Clin Endocrinol (Oxf) (2007) 1.50
90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol (2010) 1.49
The orexigenic effect of ghrelin is mediated through central activation of the endogenous cannabinoid system. PLoS One (2008) 1.49
Clinical and endocrine responses to pituitary radiotherapy in pediatric Cushing's disease: an effective second-line treatment. J Clin Endocrinol Metab (2003) 1.47
Habitual physical activity is associated with intrahepatic fat content in humans. Diabetes Care (2007) 1.45
The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. J Clin Endocrinol Metab (2008) 1.42
Current treatment protocols can offer a normal or near-normal quality of life in the majority of patients with non-functioning pituitary adenomas. Clin Endocrinol (Oxf) (2013) 1.39
Clinical manifestations of familial paraganglioma and phaeochromocytomas in succinate dehydrogenase B (SDH-B) gene mutation carriers. Clin Endocrinol (Oxf) (2008) 1.32
Rathke's cleft cysts. Clin Endocrinol (Oxf) (2012) 1.32
Insulin resistance and whole body energy homeostasis in obese adolescents with fatty liver disease. Am J Physiol Endocrinol Metab (2006) 1.32
CT and MR imaging of unusual locations of extra-adrenal paragangliomas (pheochromocytomas). Eur Radiol (2004) 1.29
Expanding role of AMPK in endocrinology. Trends Endocrinol Metab (2006) 1.29
Paraneoplastic syndromes secondary to neuroendocrine tumours. Endocr Relat Cancer (2010) 1.26
Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms. Endocr Relat Cancer (2008) 1.25
Spectrum and prevalence of FP/TMEM127 gene mutations in pheochromocytomas and paragangliomas. JAMA (2010) 1.22
The optimal imaging of adrenal tumours: a comparison of different methods. Endocr Relat Cancer (2007) 1.19
Macrophage migration inhibitory factor exhibits a pronounced circadian rhythm relevant to its role as a glucocorticoid counter-regulator. Immunol Cell Biol (2003) 1.19
Lymphoma metastasizing to the pituitary: an unusual presentation of a treatable disease. Pituitary (2005) 1.18
The ectopic ACTH syndrome. Rev Endocr Metab Disord (2010) 1.18
Free and total cortisol levels as predictors of severity and outcome in community-acquired pneumonia. Am J Respir Crit Care Med (2007) 1.15
Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours. Clin Endocrinol (Oxf) (2008) 1.15
Work-up and management of paediatric Cushing's syndrome. Curr Opin Endocrinol Diabetes Obes (2008) 1.15
Diagnostic accuracy of an "amended" insulin-glucose ratio for the biochemical diagnosis of insulinomas. Ann Intern Med (2013) 1.15
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: follow-up and documentation. Neuroendocrinology (2009) 1.15
Genetic analysis of mitochondrial complex II subunits SDHD, SDHB and SDHC in paraganglioma and phaeochromocytoma susceptibility. Clin Endocrinol (Oxf) (2003) 1.14
Fibrosis and carcinoid syndrome: from causation to future therapy. Nat Rev Endocrinol (2009) 1.12
Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line. Neuroendocrinology (2007) 1.11
AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: a novel mechanism in Cushing's syndrome. FASEB J (2008) 1.11
Contrasting clinical manifestations of SDHB and VHL associated chromaffin tumours. Endocr Relat Cancer (2009) 1.09
Clinical and biochemical characteristics of adrenocorticotropin-secreting macroadenomas. J Clin Endocrinol Metab (2005) 1.09
Ghrelin exerts a proliferative effect on a rat pituitary somatotroph cell line via the mitogen-activated protein kinase pathway. Eur J Endocrinol (2004) 1.07
Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours. Eur J Endocrinol (2004) 1.06
BRAF V600E mutations are characteristic for papillary craniopharyngioma and may coexist with CTNNB1-mutated adamantinomatous craniopharyngioma. Acta Neuropathol (2014) 1.05
Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status. Eur J Clin Invest (2011) 1.05
Signaling pathways in pheochromocytomas and paragangliomas: prospects for future therapies. Endocr Pathol (2012) 1.05
Endocrine manifestations in Langerhans cell histiocytosis. Trends Endocrinol Metab (2007) 1.05
Adrenal incidentalomas: 'the rule of four'. Clin Med (2008) 1.04
Medullary thyroid cancer: molecular biology and novel molecular therapies. Neuroendocrinology (2009) 1.04
Paediatric Cushing's syndrome: epidemiology, investigation and therapeutic advances. Trends Endocrinol Metab (2007) 1.02
Fasting and postprandial hyperghrelinemia in Prader-Willi syndrome is partially explained by hypoinsulinemia, and is not due to peptide YY3-36 deficiency or seen in hypothalamic obesity due to craniopharyngioma. J Clin Endocrinol Metab (2005) 1.02
Characterization of aryl hydrocarbon receptor interacting protein (AIP) mutations in familial isolated pituitary adenoma families. Hum Mutat (2010) 1.01
The role of AMP-activated protein kinase in obesity. Front Horm Res (2008) 1.01
Differential gene expression in pituitary adenomas by oligonucleotide array analysis. Eur J Endocrinol (2005) 1.00
Changes in adenosine 5'-monophosphate-activated protein kinase as a mechanism of visceral obesity in Cushing's syndrome. J Clin Endocrinol Metab (2008) 1.00
What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics. Eur J Endocrinol (2007) 0.99
Are neuroendocrine tumours a feature of tuberous sclerosis? A systematic review. Endocr Relat Cancer (2008) 0.99
Measurement of serum free cortisol shows discordant responsivity to stress and dynamic evaluation. J Clin Endocrinol Metab (2007) 0.99
Insulinomas may present with normoglycemia after prolonged fasting but glucose-stimulated hypoglycemia. J Clin Endocrinol Metab (2006) 0.98
Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review. Eur J Endocrinol (2012) 0.98
Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway. J Clin Endocrinol Metab (2012) 0.98
Retinoic acid as a novel medical therapy for Cushing's disease in dogs. Endocrinology (2006) 0.97
ARMC5 mutations are common in familial bilateral macronodular adrenal hyperplasia. J Clin Endocrinol Metab (2014) 0.97
The pathophysiology of pituitary adenomas. Best Pract Res Clin Endocrinol Metab (2009) 0.97
Opioid induced hypogonadism. BMJ (2010) 0.96
Radiation-induced hypopituitarism. Endocr Relat Cancer (2009) 0.95
The prevalence and characteristic features of cyclicity and variability in Cushing's disease. Eur J Endocrinol (2009) 0.95
Abnormal left ventricular energy metabolism in obese men with preserved systolic and diastolic functions is associated with insulin resistance. Diabetes Care (2007) 0.94
Association studies on ghrelin and ghrelin receptor gene polymorphisms with obesity. Obesity (Silver Spring) (2009) 0.94
Adrenocortical carcinoma: the range of appearances on CT and MRI. AJR Am J Roentgenol (2011) 0.94
Clinical, genetic and molecular characterization of patients with familial isolated pituitary adenomas (FIPA). Trends Endocrinol Metab (2010) 0.94
Assessment of p27 (cyclin-dependent kinase inhibitor 1B) and aryl hydrocarbon receptor-interacting protein (AIP) genes in multiple endocrine neoplasia (MEN1) syndrome patients without any detectable MEN1 gene mutations. Clin Endocrinol (Oxf) (2008) 0.94
Expression of phosphorylated p27(Kip1) protein and Jun activation domain-binding protein 1 in human pituitary tumors. J Clin Endocrinol Metab (2002) 0.94
Elevated fasting plasma ghrelin in prader-willi syndrome adults is not solely explained by their reduced visceral adiposity and insulin resistance. J Clin Endocrinol Metab (2004) 0.94
A rapid method for analyzing serum pro-insulin-like growth factor-II in patients with non-islet cell tumor hypoglycemia. J Clin Endocrinol Metab (2005) 0.94
Mini-review: pheochromocytomas causing the ectopic ACTH syndrome. Endocrine (2012) 0.93
Combined inhibition of mTORC1 and mTORC2 signaling pathways is a promising therapeutic option in inhibiting pheochromocytoma tumor growth: in vitro and in vivo studies in female athymic nude mice. Endocrinology (2013) 0.92
Pheochromocytomas and paragangliomas: assessment of malignant potential. Endocrine (2011) 0.92
The clinical presentation (symptoms and signs) of sporadic and familial chromaffin cell tumours (phaeochromocytomas and paragangliomas). Front Horm Res (2004) 0.92
Nonfunctioning pituitary adenomas: the Oxford experience. Nat Rev Endocrinol (2009) 0.92
Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors. Adv Ther (2010) 0.92
Diagnosis and localisation of insulinoma: the value of modern magnetic resonance imaging in conjunction with calcium stimulation catheterisation. Eur J Endocrinol (2010) 0.92
Prepubertal Cushing's disease is more common in males, but there is no increase in severity at diagnosis. J Clin Endocrinol Metab (2004) 0.91
The role of ghrelin and ghrelin-receptor gene variants and promoter activity in type 2 diabetes. Eur J Endocrinol (2009) 0.91
CT and MR imaging of the adrenal glands in ACTH-independent cushing syndrome. Radiographics (2004) 0.91
A variation in the ghrelin gene increases weight and decreases insulin secretion in tall, obese children. J Clin Endocrinol Metab (2002) 0.91
Combined blockade of signalling pathways shows marked anti-tumour potential in phaeochromocytoma cell lines. J Mol Endocrinol (2012) 0.90
Heterogeneous genetic background of the association of pheochromocytoma/paraganglioma and pituitary adenoma: results from a large patient cohort. J Clin Endocrinol Metab (2014) 0.90